Chronic Inflammation, Inflammaging
Conditions
Keywords
inflammatory age (iAge®), immunosenescence, immune phenotyping, systemic chronic inflammation
Brief summary
This is a decentralized, double-blind, randomized, placebo-controlled study to assess the effectiveness of different dietary supplements in decreasing systemic chronic inflammation (SCI) and lowering inflammatory age (iAge®). iAge® is a metric for age-related chronic inflammation and immune function decline calculated from a standard blood draw utilizing immune phenotyping and artificial intelligence algorithms. SCI is a natural process that occurs within the body. It is believed to accelerate the process of biological aging. As opposed to acute inflammation, iAge® is not a reflection of illness, infection, trauma or injury. It naturally occurs in the ambulatory healthy population as we age as a function of the body. This study will use immunotype specific dietary supplement formulations to improve a participant's Inflammatory Age® (iAge®).
Detailed description
This decentralized, double-blind, randomized, placebo-controlled study will identify interventions that may lower a participant's inflammatory age (iAge®) and will increase the number of participants with objective and subjective health information that have associated iAge® scores. The study will also (1) correlate secondary endpoints with baseline and subsequent iAge® scores, (2) confirm the compatibility of the iAge® test with the Tasso device, ADX100 or ViveBio home blood collection systems, and (3) confirm the compatibility of the iAge® test with saliva home sample collection kit. Ambulatory adults, 18 years old and over of diverse ethnicities will be invited to participate in this study from a single site in Marin County. We will choose an equal number of male and female participants by selecting households within a 60 mile radius of the study site. The study involves fasting blood sample collection to measure and characterize immunomes and inflammatory biomarkers, metabolites, lipid panel, hemoglobin, hemoglobin A1C, and high-sensitivity c-reactive protein (hsCRP). Participants will be asked to provide a blood sample by routine venipuncture at Baseline and approximately 2, 4 and 7 months after the start of the dietary supplement/placebo. Participants will be given interventions to be taken daily based on their associated immunogroup cluster after each iAge® test is completed. Participants can continue on their current supplements but should not start any new supplements except those given by the study. This study has a different intervention for nine of the ten immunotype clusters. All interventions are i) generally recognized as safe (GRAS) or ii) from compounds at similar concentrations to those found in foods. Participants will be placed in one of ten immunotype clusters after each iAge® test and randomized either to a placebo or the given formulation to be taken once daily (either one, two or three pills depending on the formulation). A participant who changes his/her immunotype cluster after a follow up iAge® test will be given a new dietary intervention (or placebo based on their previous category). All participants will also be given a Whoop wearable watch to collect information on strain, sleep and heart rate variability. Participants will be asked to complete questionnaires assessing mood, stress level, well-being, cognition, health and lifestyle. We will also obtain the following measurements: (1) Height and weight, (2) blood pressure, (3) waist and hip measurements, (4) pulse wave velocity (PWV) to measure arterial stiffness (5) timed up and go to assess frailty and (6) facial and scalp photos. A gut microbiome sampling using a third party kit for fecal collection will be obtained at each designated time point from those participants who agree to have fecal sample collection. A subset of participants will have the following procedures done at any time point during the study: (1) saliva collection, (2) heel bone density, (3) audiometry test, (4) home blood sample collection using the Tasso device, ADX100, and ViveBio device.
Interventions
DIETARY_SUPPLEMENTDietary supplement
iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate
OTHERPlacebo
Matched Placebo to Intervention
Sponsors
Edifice Health
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Participants will receive a formulation of dietary supplements based on the iAge test. Different formulations contain different combinations of dietary supplements.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18+ years old * Ambulatory * Willing and able to comply with the study protocol
Exclusion criteria
* Participants with any condition that may preclude venipuncture or venous blood draws will be excluded. * Participants with known allergies to interventions will be removed from the study. * Vulnerable subjects including children, employees and those with cognitive disabilities will not be included in this study. * Male participants on iron supplementation * Participants on \>1 mg manganese, \>5 mg biotin * Pregnant women * Nursing women * Membership in the clinical study team * Any condition that might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol At the time of enrollment: * Active systemic or serious concurrent illness * History of immunodeficiency * Any known or suspected impairment of immunologic function * Diabetes mellitus treated with any diabetic medication * Moderate to severe renal disease * Blood pressure greater than 140/90 * Chronic hepatitis B or C * Recent or current use of immunosuppressive medication * Malignancy other than squamous cell or basal cell skin cancer, including solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia, which might jeopardize volunteer safety or compliance with the protocol * Autoimmune disease * Auto-inflammatory disease * History of blood dycrasias or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year * Use of any anticoagulation medication * A medical or psychiatric condition or occupational responsibilities that would preclude subject compliance with the protocol * History of Guillain-Barre syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in inflammatory age (iAge®) scores from Baseline to end of study intervention | Measured at Baseline, Day 50, Day 120 and Day 210 | Measurement of iAge® scores in all study participants. Peripheral blood samples will be collected, processed and analyzed and iAge is measured using standardized procedures, immune phenotyping and artificial intelligence algorithms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in immune protein biomarkers from Baseline to end of study intervention | Measured at Baseline, Day 50, Day 120 and Day 210 | Blood sample measurements of the levels of the biomarkers Eotaxin-1 (CCL11), Interferon-gamma, Growth Regulated Oncogene-alpha, Monokine Induced by Gamma Interferon (MIG) and TNF-related Apoptosis Inducing Ligand (TRAIL) |
| Change in values for hemoglobin, A1C, high sensitivity C-reactive protein (hs-CRP), and lipid panel from Baseline to end of study intervention | Measured at Baseline, Day 50, Day 120 and Day 210 | Blood samples measured for hemoglobin, A1C, hs-CRP, and lipid panel |
| Anthropometric and metabolic measurements from Baseline to end of study intervention | Measured at Baseline, Day 50, Day 120 and Day 210 | Measurement of height, weight, body mass index (BMI), waist-to-hip ratio |
| Change in cardiovascular health from Baseline to end of study intervention | Measured at Baseline, Day 50, Day 120 and Day 210 | Measurement of blood pressure, pulse wave velocity using the Whithings Cardio device and heart rate variability with the Whoop wearable |
| Correlation of iAge score with ankle bone density score | Measured at a single time point during the duration of the study | Measurement of ankle bone density using the GE Achilles Lunar Express ultrasonometer |
| Correlation of iAge score with hearing test score | Measured at a single time point during the duration of the study | Measurement of hearing acuity using the Shoebox Audiometry System |
| Change in frailty and mobility from Baseline to end of study intervention | Measured at Baseline and Day 210 | Timed Up and Go (TUG) test will be use to measure the length of time in seconds it takes for the participant to stand from a chair, walk 3 meters, turn around and sit back in the chair. TUG is a simple sensitive test to assess mobility, balance, walking ability, and fall risk in older adults. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assessment of skin and scalp health from Baseline to end of study intervention | Measured at Baseline, Day 50, Day 120 and Day 210 | Facial and scalp photos will be taken using an iPAD |
| Saliva sample collection | Measured at Baseline in a subset of participants | General and oral health assessment through saliva sample collection in a subset of participants |
| Changes in the gut microbiome at Baseline to end of study intervention in a subset of participants | Measured at a single time point during the duration of the study in a subset of participants | Evaluate changes in the gut microbiome using the Thryve Gut Health Test Kit to collect stool samples |
| Correlation of standard venipuncture with at-home Tasso, ADX100m and ViveBio collection system in predicting iAge | Measured at Baseline in a subset of participants | Capillary blood collection using the at-home Tasso, ADX100 and ViveBio collection system in a subset of study participants |
| Changes in metabolomic profile | Measured at Baseline, Day 50, Day 120 and Day 210 in a subset of participants | In a subset of participants, metabolite analysis of blood plasma using high-throughput technology |
| Skin pH | Measured at Baseline, Day 50, Day 120 and Day 210 in a subset of participants | Skin pH probe |
| Track fitness performance biometrics from Baseline to end of study intervention | Measured at Baseline, Day 50, Day 120 and Day 210 | Measurement and monitoring of sleep, strain, and heart rate variability using the WHOOP wearable device |
Countries
United States
Outcome results
None listed